Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
First-line treatment with nivolumab plus ipilimumab resulted in a longer duration of overall survival than did chemotherapy in patients with NSCLC, independent of the PD-L1 expr...
Publications
2 shownAtezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Atezolizumab treatment resulted in significantly longer overall survival than platinum-based chemotherapy among patients with NSCLC with high PD-L1 expression, regardless of his...
Frequent Co-Authors
Researcher Info
- h-index
- 2
- Publications
- 2
- Citations
- 4,276
- Institution
- Université de Limoges
External Links
Identifiers
- ORCID
- 0000-0002-5356-6070
Impact Metrics
h-index
2
h-index: Number of publications with at least h citations each.